Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest data from a Phase ...

The liposarcoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage liposarcoma drugs, inactive and dormant assets, a comprehensive ...

This study identifies 53BP1 as an interaction partner of GMCL1 (a likely CUL3 substrate receptor). The study seeks to link this finding to regulation of the mitotic surveillance pathway and paclitaxel ...

Scientists have recently shed some light on exactly why elephants, one of the biggest animals on the planet, paradoxically ...

Pathos also took ownership of the phase 3-stage MDM2 inhibitor milademetan as part of its acquisition of Rain Oncology in December 2023. However, Pathos hasn’t name-checked the failed ...

The small molecules in question are ASTX029, an ERK1/2 inhibitor that has completed a phase 2 study, and ASTX295 an MDM2 antagonist that has undergone a phase 1 trial. Both candidates have ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers ...

MDM2, on the other hand, is one of the most frequently studied oncogenes and is an excellent target for cancer therapy, based on its p53-dependent and p53-independent oncogenic activities in ...

MDM2, on the other hand, is one of the most frequently studied oncogenes and is an excellent target for cancer therapy, based on its p53-dependent and p53-independent oncogenic activities in ...

Brigimadlin, a member of the MDM2-p53 antagonist drug class, recently entered a pivotal trial testing the candidate in patients with the rare cancer dedifferentiated liposarcoma (DDLPS).